We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......

Antiretroviral Therapy for Adult HIV-lnfected Patients:  Recommendations From a State-of-the-Art Conference

Merle A. Sande, MD; Charles C. J. Carpenter, MD; C. Glenn Cobbs, MD; King K. Holmes, MD, PhD; Jay P. Sanford, MD; Robert W. Coombs, MD, PhD; Thomas R. Fleming, PhD; Rebecca Denison; Mitchell H. Gail, MD, PhD; Wayne Lamar Greaves, MD; Martin S. Hirsch, MD; Roberta Luskin-Hawk, MD; Donna Mildvan, MD; Charles A. Nelson; John P. Phair, MD; Robert Schooley, MD; R. Gabriel Torres, MD; Robert Vazquez; Lawrence Deyton, MSPH, MD; John Jermano, RN, MPH; Juanita Koziol, RN, MS, CS; Carla Pettinelli, MD, PhD; Debbie Katz, RN, MS
JAMA. 1993;270(21):2583-2589. doi:10.1001/jama.1993.03510210069030.
Text Size: A A A
Published online

This document summarizes recommendations from a state-of-the-art conference convened to evaluate the role of nucleoside analogue reverse transcriptase inhibitors in the treatment of human immunodeficiency virus (HIV) infection. Data from controlled clinical trials of zidovudine, didanosine, and zalcitabine were reviewed by an expert panel, which then formulated guidelines to assist clinicians and HIV-infected patients in the use of these agents. Recommendations were framed in the context of clinical scenarios for patients with asymptomatic HIV infection who have not had prior antiretroviral therapy; those with signs and symptoms of HIV-related disease who have not received prior therapy; clinically stable patients who are tolerating initial zidovudine therapy; patients experiencing clinical progression while on zidovudine therapy; and those who are intolerant of antiretroviral therapy. The panel concluded that physicians need to integrate up-to-date scientific knowledge with other relevant needs to improve the care of HIV-infected patients.

(JAMA. 1993;270:2583-2589)


Sign in

Purchase Options

• Buy this article
• Subscribe to the journal




Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal

Related Content

Customize your page view by dragging & repositioning the boxes below.